Hanmi Pharmaceutical Company Limited
hanmi.co.krTotal trials
187
Active
14
Phase 3
36
Total enrollment
52,995
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| HM11260C | — | — | — | 8 | |||
| HGP2102-1 | — | — | — | — | — | 1 | |
| HGP2102-2 | — | — | — | — | — | 1 | |
| RLD2209-1 | — | — | — | — | — | 1 | |
| RLD2209-2 | — | — | — | — | — | 1 | |
| HM15275 | — | — | — | — | 3 | ||
| HM15136 | — | — | — | — | 3 | ||
| HM15211 | — | — | — | — | 2 | ||
| HM15912 Active | — | — | — | — | — | 1 | |
| Belvarafenib | — | — | — | — | — | 1 | |
| Cobimetinib | — | — | — | — | — | 1 | |
| pembrolizumab | — | — | — | — | 3 | ||
| HCP1306 | — | — | — | — | — | 5 | |
| HM16390 | — | — | — | — | — | 1 | |
| BH3120 | — | — | — | — | — | 1 | |
| HM97662 | — | — | — | — | — | 1 | |
| HM17321 | — | — | — | — | — | 1 | |
| HIP2503 | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-03-25
- 2026-06-27
- 2026-07
- 2026-12-31
- 2027-01
- 2027-03
- 2027-08
- 2027-09
- 2027-11
Top conditions
- Healthy51
- Hypertension22
- Diabetes Mellitus8
- Obesity6
- Erectile Dysfunction5
- Hyperlipidemia4
- Type 2 Diabetes Mellitus4
- Non Small Cell Lung Cancer4
Frequently asked questions about Hanmi Pharmaceutical Company Limited
- How many clinical trials does Hanmi Pharmaceutical Company Limited have on ClinicalTrials.gov?
- Hanmi Pharmaceutical Company Limited is listed as the lead sponsor on 187 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hanmi Pharmaceutical Company Limited's trials are in Phase 3?
- 36 of Hanmi Pharmaceutical Company Limited's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Hanmi Pharmaceutical Company Limited focus on?
- Hanmi Pharmaceutical Company Limited's most-studied conditions on ClinicalTrials.gov are Healthy, Hypertension, Diabetes Mellitus, Obesity, Erectile Dysfunction.
- When are Hanmi Pharmaceutical Company Limited's next clinical trial readouts?
- Hanmi Pharmaceutical Company Limited has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus”, expected around 2025-12-31.